

## Saoirse E. O'Sullivan, PhD

Artelo Biosciences Ltd., Stockport, United Kingdom

Professor Saoirse Elizabeth O'Sullivan (@ScienceSaoirse) received her doctorate from Trinity College Dublin in 2001 and moved to the University of Nottingham in 2002 as a Research fellow where she began researching cannabinoid pharmacology. She was made Lecturer in 2007, Associate Professor in 2011 and Full Professor in 2019. She has more than 60 peer-reviewed articles and 3 books chapters on cannabinoid pharmacology. Her academic interests were on the therapeutic potential of cannabinoid-based therapies in cardiovascular disease, diabetes, cancer and inflammatory bowel disease. Her research methodologies spanned from cellular and animal models, to human healthy volunteer studies, systematic reviews and early phase clinical trials. Saoirse left academic in 2019 and is now the Vice President of Translational Sciences at Artelo Biosciences ([Home - Artelo Biosciences](#)), running the preclinical research strategy of multiple pipelines including a peripheral restricted CB<sub>1</sub> agonist (being trialled in cachexia), a cannabidiol cocrystal (for use in anxiety/depression), and a fatty acid binding protein (FABP) inhibitor platform (lead molecule is being investigated in peripheral neuropathy). She also runs an independent consulting company called CanPharmaConsulting Ltd, acting as scientific advisor to other pharmaceutical and biotech companies.

Website:

